AMST vs CVKD Comparison

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.